Advertisement
News
Subscribe to MDT Magazine News

Bayer Gets $100M Gender Class Action Headache

March 21, 2011 9:38 am | by Bio-Medicine.Org | Comments

NEWARK, N.J., March 21, 2011 /- Bayer HealthCare Pharmaceuticals was handed a pounding $100 million headache today that even its highly-publicized aspirin is unlikely to relieve.  The law firm of Sanford Wittels & Heisler, LLP, filed a class action complaint in U.S. District...

TOPICS:

Branded Pharmaceutical Websites Continue to Be Most Impactful in Driving Conversions Among Prospects and Patients

March 21, 2011 9:37 am | by Bio-Medicine.Org | Comments

RESTON, Va., March 21, 2011 /- comScore, Inc. (Nasdaq: SCOR ), a leader in measuring the digital world, today released results from its fifth annual Online Marketing Effectiveness Benchmarks for the Pharmaceutical Industry. The study supports previous findings that exposure to online...

TOPICS:

PharmaNet Shares Expertise in Drug Development Outsourcing at the 2011 Partnerships in Clinical Trials Conference

March 21, 2011 7:35 am | by Bio-Medicine.Org | Comments

PRINCETON, N.J., March 21, 2011 /- PharmaNet Development Group, Inc., a leading provider of drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries, announces its participation at the 19th Annual Partnerships in Clinical Trials Conference...

TOPICS:
Advertisement

Core Essence Secures $11.5 Million Series B Financing

March 21, 2011 7:35 am | by Bio-Medicine.Org | Comments

FORT WASHINGTON, Pa., March 21, 2011 /- Core Essence Orthopaedics, Inc. (Core Essence), a Fort Washington, Penn.-based orthopaedic device company, announced today it has raised $11.5 million in Series B financing. Baird Venture Partners led the round, joined by existing investor NewSpring...

TOPICS:

Alzheimer's Drug Discovery Foundation Supports ADispell Technology with a Grant to Advance Novel Drug Candidates for Alzheimer's Disease

March 21, 2011 7:34 am | by Bio-Medicine.Org | Comments

NEW YORK, March 21, 2011 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced that it has awarded a grant of $170,750 to ADispell Inc. to develop small molecule drugs designed to halt the progression of cognition loss that occurs with Alzheimer's Disease....

TOPICS:

Heygood, Orr & Pearson: Los Angeles Court Orders Watson Pharmaceuticals to Produce Documents, Provide Depositions in Fentanyl Patch Death Lawsuit

March 21, 2011 7:32 am | by Bio-Medicine.Org | Comments

LOS ANGELES, March 21, 2011 /- Attorneys from Dallas' Heygood, Orr & Pearson are announcing a Los Angeles Superior Court ruling that will require executives from Watson Pharmaceuticals Inc. (NYSE: WPI ) and its subsidiary companies to testify under oath and produce key documents as...

TOPICS:

Despite New Changes, Highmark Policy Still Threatens Patients With Primary Immunodeficiency Diseases

March 21, 2011 7:32 am | by Bio-Medicine.Org | Comments

HARRISBURG, Pa., March 21, 2011 /- Beginning April 1, Highmark Blue Cross Blue Shield (Highmark) will force a number of their insured patients with primary immunodeficiency diseases and other rare disorders to switch their prescription to a single brand of immunoglobulin (IgG - a blood...

TOPICS:

Curis, Genentech announce cancer drug study result

March 21, 2011 6:45 am | by The Associated Press | Comments

Drug developer Curis Inc. said Monday a mid-stage trial of a potential cancer treatment it is studying with Roche's Genentech unit shrank tumors in patients with an advanced form of skin cancer.The treatment, labeled vismodegib, was tested in a study involving 104 patients with advanced basal...

Advertisement

Synageva finds $25M financing for enzyme treatment

March 21, 2011 6:38 am | by Mass High Tech: The Journal of New England Technology | Comments

Synageva BioPharma Corp. has landed a $25 million private equity funding to support development of the Lexington biotech's enzyme replacement therapy, SBC-102.

CardioFocus claims $5M credit line with Silicon Valley Bank

March 21, 2011 6:38 am | by Mass High Tech: The Journal of New England Technology | Comments

Marlborough medical device company CardioFocus Inc. has landed the anticipated $5 million credit facility from Silicon Valley Bank, which the company says it will use to start a U.S. trial of its Endoscopic Ablation System in heart surgery.

Curemark Completes Enrollment of Phase III Autism Trials

March 21, 2011 6:36 am | by Bio-Medicine.Org | Comments

RYE, N.Y., March 21, 2011 /- Curemark, LLC , ( www.curemark.com ), a drug research and development company focused on the treatment of neurological diseases, announced that the company has completed its targeted enrollment of Phase III clinical trials for CM-AT , its autism treatment....

TOPICS:

Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering

March 21, 2011 6:34 am | by Bio-Medicine.Org | Comments

MADISON, N.J., March 21, 2011 /- Quest Diagnostics Incorporated (the "Company") (NYSE:  DGX), the world's leading provider of diagnostic testing, information and services, announced today that it intends to offer $1,250,000,000 in aggregate principal amount of four series of senior...

TOPICS:

PositiveID Corporation to Debut Its iglucose Mobile Health Diabetes Management Solution at CTIA Wireless 2011

March 21, 2011 5:31 am | by PositiveID | Comments

PositiveID Corporation to Debut Its iglucose Mobile Health Diabetes Management Solution at CTIA Wireless 2011

TOPICS:

NeuroFocus Announces World's First Wireless Full-Brain EEG Measurement Headset: Myndâ„¢

March 21, 2011 4:36 am | by Bio-Medicine.Org | Comments

NEW YORK, March 21, 2011 /- NeuroFocus unveiled the first dry, wireless headset designed to capture brainwave activity across the full brain today at the 75th Annual Advertising Research Foundation conference being held at the Marriott Marquis in New York.  Developed over the last...

TOPICS:

Life Technologies Initiates Clinical Trials Leading to 510(k) Submission of a Class I and Class II HLA Sequence-Based Typing Solution

March 21, 2011 4:35 am | by Bio-Medicine.Org | Comments

CARLSBAD, Calif., March 21, 2011 /- Life Technologies Corporation (Nasdaq: LIFE ) today announced that it is the first life science tools provider entering clinical trials to prove the safety and effectiveness of their DNA sequence-based typing (SBT) platform for analysis of the Human...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading